S G Meuth1, T Ruck2, O Aktas3, H-P Hartung3. 1. Klinik für Neurologie mit Institut für Translationale Neurologie, Universitätsklinikum Münster, Albert-Schweitzer-Campus 1, Gebäude A1, Westturm, Ebene 05, 48149, Münster, Deutschland. sven.meuth@ukmuenster.de. 2. Klinik für Neurologie mit Institut für Translationale Neurologie, Universitätsklinikum Münster, Albert-Schweitzer-Campus 1, Gebäude A1, Westturm, Ebene 05, 48149, Münster, Deutschland. 3. Klinik für Neurologie, Universitätsklinikum Düsseldorf, Heinrich-Heine-Universität, Düsseldorf, Deutschland.
Abstract
BACKGROUND: The selective modulation of lymphocyte numbers and function is an attractive concept in the treatment of relapsing-remitting multiple sclerosis (RMS). OBJECTIVE: Cladribine tablets (Mavenclad®), an oral RMS medication with an innovative treatment concept, have been available since August 2017. This review article summarizes the currently available clinical study data on cladribine tablets and aspects of their use in clinical practice. RESULTS: Cladribine tablets are administered during two treatment phases of 8-10 (two times 4-5) days with a 1-year interval. The drug selectively reduces the number of T and B lymphocytes, which are subsequently gradually reconstituted with divergent kinetics. A pronounced and sustained effect on the clinical and paraclinical MS disease activity is achieved with good tolerability and a favorable overall safety profile. After completing the two short treatment phases, a relevant proportion of the treated patients experience a prolonged treatment-free period with absence of relevant disease activity. Regular monitoring of lymphocyte counts and reliable contraception during the required time frames are the most important safety measures. There is no evidence of an increased risk of malignancies. CONCLUSION: Cladribine tablets are an important addition to the therapeutic landscape in RMS. With patient-friendly short dosing periods and a favorable adverse event profile, cladribine tablets provide a sustained and strong reduction of MS disease activity. The primary target population for cladribine tablets is patients with relevant MS disease activity (highly active RMS) while on first-line treatment, e. g. with injectable disease-modifying drugs.
BACKGROUND: The selective modulation of lymphocyte numbers and function is an attractive concept in the treatment of relapsing-remitting multiple sclerosis (RMS). OBJECTIVE:Cladribine tablets (Mavenclad®), an oral RMS medication with an innovative treatment concept, have been available since August 2017. This review article summarizes the currently available clinical study data on cladribine tablets and aspects of their use in clinical practice. RESULTS:Cladribine tablets are administered during two treatment phases of 8-10 (two times 4-5) days with a 1-year interval. The drug selectively reduces the number of T and B lymphocytes, which are subsequently gradually reconstituted with divergent kinetics. A pronounced and sustained effect on the clinical and paraclinical MS disease activity is achieved with good tolerability and a favorable overall safety profile. After completing the two short treatment phases, a relevant proportion of the treated patients experience a prolonged treatment-free period with absence of relevant disease activity. Regular monitoring of lymphocyte counts and reliable contraception during the required time frames are the most important safety measures. There is no evidence of an increased risk of malignancies. CONCLUSION:Cladribine tablets are an important addition to the therapeutic landscape in RMS. With patient-friendly short dosing periods and a favorable adverse event profile, cladribine tablets provide a sustained and strong reduction of MS disease activity. The primary target population for cladribine tablets is patients with relevant MS disease activity (highly active RMS) while on first-line treatment, e. g. with injectable disease-modifying drugs.
Entities:
Keywords:
Disease activity; Mode of action; Pharmacokinetics; Pulsed treatment; Side effects
Authors: Kottil Rammohan; Gavin Giovannoni; Giancarlo Comi; Stuart Cook; Peter Rieckmann; Per Soelberg Sørensen; Patrick Vermersch; Anthony Hamlett; Nuwan Kurukulasuriya Journal: Mult Scler Relat Disord Date: 2011-09-15 Impact factor: 4.339
Authors: Gavin Giovannoni; Per Soelberg Sorensen; Stuart Cook; Kottil Rammohan; Peter Rieckmann; Giancarlo Comi; Fernando Dangond; Abidemi K Adeniji; Patrick Vermersch Journal: Mult Scler Date: 2017-09-05 Impact factor: 6.312
Authors: A Cohen; R Hirschhorn; S D Horowitz; A Rubinstein; S H Polmar; R Hong; D W Martin Journal: Proc Natl Acad Sci U S A Date: 1978-01 Impact factor: 11.205
Authors: Julia Pakpoor; Giulio Disanto; Daniel R Altmann; Sue Pavitt; Benjamin P Turner; Monica Marta; Gunnar Juliusson; David Baker; Jeremy Chataway; Klaus Schmierer Journal: Neurol Neuroimmunol Neuroinflamm Date: 2015-10-01
Authors: Ludwig Kappos; Gilles Edan; Mark S Freedman; Xavier Montalbán; Hans-Peter Hartung; Bernhard Hemmer; Edward J Fox; Frederik Barkhof; Sven Schippling; Andrea Schulze; Dirk Pleimes; Christoph Pohl; Rupert Sandbrink; Gustavo Suarez; Eva-Maria Wicklein Journal: Neurology Date: 2016-08-10 Impact factor: 9.910